You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

June 29, 2015

The International Comparative Legal Guide to: Pharmaceutical Advertising 2015 – Vietnam Chapter

Subscribe to Updates
Global Legal Group

Kien Trung Trinh, senior attorney-at-law, and Tu Ngoc Trinh, attorney-at-law, in Tilleke & Gibbins’ Hanoi office, have co-authored the Vietnam chapter of The International Comparative Legal Guide to: Pharmaceutical Advertising 2015 (12th edition), a Q&A-style guide that provides practical, cross-border insight into pharmaceutical advertising across 35 jurisdictions. The Vietnam chapter covers the following main topics:

  • Medicinal Products in General: Laws and codes of practice, definition of “advertising,” company compliance arrangements, standard operating procedures, regulatory or industry authority approval, penalties for noncompliance, relationship between self-regulatory processes and function of competent authorities, and unfair competition.
  • Providing Information Prior to Authorization of Medicinal Products: Making information available to healthcare professionals before a medicinal product is authorized, publishing information on unauthorized medicines and/or off-label information, and using healthcare professionals in market research exercises concerning possible launch materials for medicinal products that are unauthorized.
  • Advertisements to Healthcare Professionals: Advertisement requirements and restrictions, rules governing comparative advertisements, rules governing the distribution of scientific papers and/or proceedings of congresses to healthcare professionals, and “teaser” advertisements.
  • Gifts and Financial Incentives: Providing medicinal product samples to healthcare professionals, giving gifts or donations, volume-related discounts, refund schemes, and sponsoring medical education.
  • Hospitality and Related Payments: Offering hospitality to healthcare professionals and paying healthcare professionals to provide expert services and take part in post-marketing surveillance studies and market research involving promotional materials.
  • Advertising to the General Public: Advertising prescription-only and nonprescription medicines, press releases, describing products and research initiatives as background information in corporate brochures and annual reports, and meetings with and funding of patent organizations.
  • Transparency and Disclosure: Obligations to disclose details of ongoing and/or completed clinical trials and requirements to make information public.
  • The Internet: Regulations, website security, content of independent websites that may be accessed by a link from a company-sponsored site, permitted information on pharmaceutical company websites, and social media.
  • Developments in Pharmaceutical Advertising: Significant developments and general practice or enforcement trends.

The ICLG series, published by the Global Legal Group, provides multi-jurisdictional insight into a range of legal areas.

This article appeared in the 2015 edition of The International Comparative Legal Guide to: Pharmaceutical Advertising; published by Global Legal Group Ltd, London. (www.iclg.co.uk )

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Corporate/M&A

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
Read More
October 3, 2025
On September 26, 2025, the Contract Committee under Thailand’s Consumer Protection Board issued a regulation that aims to standardize contracts and enhance consumer protection within the beauty and wellness industry. The Notification on Prescribing the Beauty Service Business as a Contract-Controlled Business B.E. 2568 (2025), which takes effect on January 24, 2026, requires business operators to use a prescribed standard contract in Thai and adhere to strict mandatory provisions and prohibitions. These regulations apply to operators across all in-person and online service channels, including via digital platforms. “Beauty services business” is defined as the provision of services under an agreement allowing consumers to receive a series of treatments, either over a set number of sessions or within a set period. This includes massage, spa, other methods for cleanliness, beauty, or care of facial or body skin, and weight control and body shaping—including services offered electronically. The law excludes surgery, liposuction, and medical treatments performed by licensed practitioners. The notification establishes the following key requirements: Mandatory contract and formatting. All contracts with consumers must use the standard contract form, in Thai, with clear, readable text (minimum font size of 2 millimeters, no more than 11 characters per inch), and include all essential terms from the annexed form. Contract execution. Contracts must be made in duplicate, with one copy given to the consumer at signing. For agreements concluded through electronic channels, the process must comply with the Electronic Transactions Act and use the same required terms. Digital platforms. Business operators who provide services facilitated through a digital platform as an intermediary are ultimately responsible for ensuring the consumer receives a compliant contract. Prohibited clauses. The law prohibits clauses that limit or exclude liability for damages to life, body, health, mind, or property resulting from breach of contract or a wrongful act;
Read More
September 16, 2025
Since Thailand formally removed Mitragyna speciosa (kratom) from the list of narcotic drugs, the country has progressed from outright prohibition to a structured, license-based regime. While the Ministry of Public Health oversees cannabis plant regulation, the Ministry of Justice (MOJ) is the regulatory authority overseeing kratom plants. For the avoidance of doubt, separate Ministry of Public Health notifications prohibit the use of kratom as a food ingredient unless a food safety evaluation has been conducted; however, this restriction does not affect trade in unprocessed leaves per se. For businesses in Thailand dealing exclusively in kratom leaves, the most consequential development is the Ministerial Regulation on the Application for Permits and Notifications for the Importation and Exportation of Kratom Leaves B.E. 2568 (2025), a bylaw of the Kratom Plant Act 2022. The ministerial regulation establishes the following notable definitions: “Kratom leaves”: Fresh or dried leaves in their natural, unprocessed state (no extracts, concentrates, or infused products). “Import/Export”: Any act of bringing kratom leaves into or out of Thailand, whether for commercial sale, industrial processing abroad, or research. Import/Export Licensing Under the Kratom Plant Act, a license is mandatory for importing or exporting kratom leaves. Individuals, juristic persons, community enterprises, and state agencies in Thailand are eligible to obtain a license to import (or a license to export) kratom leaves. Licenses are available to qualified individuals and juristic persons. Individuals must satisfy the following qualifications to be eligible for a license: Thai nationality, ≥ 20 years old, resident in Thailand. Not incompetent, quasi-incompetent, or under legal guardianship. No license suspension currently in force under the Kratom Act or Narcotics Code. No license revocation in the previous two years. No conviction under the Kratom Act or Narcotics Code within the previous two years (unless fully released from punishment). Juristic persons must satisfy
Read More